Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NovoCure Limited - Ordinary Shares
(NQ:
NVCR
)
13.49
-0.18 (-1.32%)
Streaming Delayed Price
Updated: 1:16 PM EST, Mar 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NovoCure Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
Today 7:00 EST
From
Novocure
Via
Business Wire
Novocure to Participate in 2026 Leerink Global Healthcare Conference
February 27, 2026
From
Novocure
Via
Business Wire
NovoCure (NVCR) Q4 2025 Earnings Call Transcript
↗
February 26, 2026
NovoCure (NVCR) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
World Trade
Novocure Ltd (NASDAQ:NVCR) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss
↗
February 26, 2026
Via
Chartmill
Earnings Scheduled For October 30, 2025
↗
October 30, 2025
Via
Benzinga
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
February 26, 2026
From
Novocure
Via
Business Wire
The market is filled with gapping stocks in Wednesday's session.
↗
February 25, 2026
Via
Chartmill
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
February 24, 2026
From
Novocure
Via
Business Wire
Soleus Adds a Significant Number of Celcuity Shares
↗
February 13, 2026
This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.
Via
The Motley Fool
AI: The Great Disruptor or the Great Divider?
↗
February 13, 2026
Via
Chartmill
NVCR Rallies On FDA Approval For Cancer Treatment Device, Analyst Still Sees 275% Potential Upside
↗
February 12, 2026
H.C. Wainwright raised the firm's price target on Novocure to $47 from $39 and kept a ‘Buy’ rating on the shares after the company announced FDA approval of Optune Pax.
Via
Stocktwits
Topics
Government
Which stocks are experiencing notable movement on Thursday?
↗
February 12, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
February 12, 2026
Via
Chartmill
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
February 12, 2026
The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of...
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
Stay updated with the stocks that are on the move in today's pre-market session.
↗
February 12, 2026
Via
Chartmill
Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today
↗
February 12, 2026
Via
Stocktwits
Topics
Stocks
Novocure Stock Surges Nearly 30% After Hours: FDA Clears First New Pancreatic Cancer Therapy In Almost Three Decades
↗
February 12, 2026
The stock is on track to record its best day since December 2024 if the overnight gains hold.
Via
Stocktwits
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
February 11, 2026
From
Novocure
Via
Business Wire
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
January 12, 2026
From
Novocure
Via
Business Wire
NovoCure (NVCR) Q4 2024 Earnings Call Transcript
↗
December 23, 2025
NovoCure (NVCR) Q4 2024 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
NovoCure (NVCR) Q3 2024 Earnings Call Transcript
↗
December 23, 2025
NovoCure (NVCR) Q3 2024 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Novocure (NVCR) Q2 2025 Earnings Call Transcript
↗
December 23, 2025
Novocure (NVCR) Q2 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
December 22, 2025
From
Novocure
Via
Business Wire
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
December 01, 2025
From
Novocure
Via
Business Wire
NovoCure (NVCR) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
NovoCure (NVCR) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
World Trade
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
November 26, 2025
From
Novocure
Via
Business Wire
2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon
↗
November 12, 2025
If you have decades of investing runway left, consider these two top healthcare stocks.
Via
The Motley Fool
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
November 12, 2025
From
Novocure
Via
Business Wire
Novocure (NASDAQ:NVCR) Q3 2025 Earnings: Revenue Beat and Narrower Loss Drive Shares Higher
↗
October 30, 2025
Novocure (NVCR) beat Q3 2025 revenue estimates and narrowed its loss, with shares rising. The oncology firm is expanding its Tumor Treating Fields therapy into new cancers.
Via
Chartmill
Novocure Reports Third Quarter 2025 Financial Results
October 30, 2025
From
Novocure
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
